GUTS (fractyl.com) Market Value to Book Value Ratio

Official company branding of Fractyl Health Inc. (GUTS)

The Fractyl Health, Inc. (GUTS) price chart on the GURU.Markets platform demonstrates the dynamics of the asset, which is currently valued at -6.83. The development of innovative therapy systems for metabolic disorders currently requires massive investment, which is temporarily increasing laboratory costs. The business relies on a staff of leading diabetologists attracted by generous stock options. Meanwhile, Fractyl Health, Inc. (GUTS) operates in a protected niche where demand for treatment remains independent of economic cycles.

GUTS Fractyl Health, Inc: Market Value to Book Value in the range 02/21/2024 - 10/28/2026

Financial and market metric breakdowns for Fractyl Health Inc. (GUTS)

- price and consensus price forecast:
Price Chart Fractyl Health, Inc.|GUTS - Analyst Median Target
- market capitalization data:
Market Value Fractyl|GUTS - Full Business Value
- book capitalization data:
Book Value per Share Fractyl Health|GUTS - Accounting Value of Company|Market Capitalization to Book Value Ratio fractyl.com|GUTS - Company Total Assets
- debt and liquidity data:
Debt to Equity Fractyl Health, Inc.|GUTS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Fractyl|GUTS - Company Total Debt|Debts to Book Capitalization Fractyl|GUTS - Company Long-Term Debts|Company Current Liabilities Fractyl Health
Initial company analysis:Fractyl Health, Inc. - GUTS
Original product of Fractyl

Fractyl Health, Inc. focuses on attracting leading biologists and researchers to develop its innovative platform. The market capitalization-to-book value ratio measures the market value premium over the issuer's net assets. The current value of -6.83 reflects investor expectations regarding the company's future breakthroughs. Exceeding industry norms signals potential returns alongside an increased risk of correction. The price action on the company's P/BV chart enables real-time benchmarking without waiting for quarterly reports.

Main competitors

Ascendis Pharma A/S - Market Value to Book Value Ratio|MDGL (madrigalpharma.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Corcept Therapeutics Incorporated CORT|Market Capitalization to Net Assets Rhythm Pharma|Akero Therapeutics Inc (AKRO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Metsera Therapeutics (MTSR)|Market Capitalization to Book Value Ratio MLTX (MoonLake Immunotherapeutics)|crinetics.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Market Value to Book Value|FOLD (Amicus Pharma) - Market Value to Book Value Ratio|89bio Pharma (ETNB) - Market Cap to Net Assets Ratio|AGIO (Agios Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio structuretx.com (GPCR)|MiMedx (MDXG) - Market Cap to Net Assets Ratio|Market Value to Book Value RZLT (Rezolute Inc)|Lexicon Pharma - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio MBX Corp MBX|ALT (Altimmune, Inc.) - Market Capitalization to Book Value Ratio|aardvarktherapeutics.com (AARD) - Market-to-Book Ratio|SGMT - Market Cap to Net Assets Ratio|BioAge Labs (BIOA) - Market Cap to Book Value Multiple|BMEA (Biomea) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Quince|Market Capitalization to Book Value Ratio vTv Therapeutics Inc. (VTVT)|Market Value to Book Value Ratio ATPC (agapeatpgroup.com)|PLUR: Market Value to Book Value Ratio|Synlogic Inc. - Market-to-Book Ratio|LPCN - Market Value to Book Value Ratio|MTNB - Market Value to Book Value Ratio|Spruce Biosciences - Market Capitalization to Book Value Ratio|GLTO (galecto.com) - Market Capitalization to Book Value|CTCX: Market Value to Book Value Ratio|Market Capitalization to Book Value LUMO|Market Value to Book Value Ratio ONVO (Organovo Holdings Inc)|Market Cap to Net Assets Ratio Radius Pharmaceuticals (RDUS)